ArticleNPJ precision oncology2023

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.

Hussein Al-Sudani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.